Europe Bioreactors Market size was valued at USD 284.0 million in 2018 and is expected to witness 17.1% CAGR from 2019 to 2025.
Europe Bioreactors Market, 2018 & 2025 (USD Mn)
Get more details on this report - Request Free Sample PDF
Europe bioreactors market is expected to witness considerable growth across the forecast timeframe. Growing demand for innovative biotech solutions such as single-use technology, pre-built modular facilities, and the ability to revamp and upgrade existing facilities in Europe will drive the industry growth over the forecast period. In Europe, several companies are developing closed systems for the growth of micro-algae. Numerous developments have taken place in recent years with the aim to increase the production. Europe has opportunities due to the advancement in algae biomass commercialization by European algae technology companies, that will further drive the bioreactor market size over the forecast period.
Growing demand for personalized medicines is another chief growth augmenting factor. The number of personalized medicines targeting a specific population of patients has increased in the recent years. Personalized medicine has a rising need for rapid, portable, flexible and scalable bio-manufacturing system that can be monitored online for consistent, safe and affordable production of biologics thus, accelerating the demand for bioreactors.
However, the anticipated growth in the bioreactors market is likely to impede due to the limitation in the capacity of single-use bioreactor. Moreover, use of disposable plastic bioreactors for biopharmaceutical manufacturing will be a market impeding factor owing to concerns related to extractables and leachable.
Europe Bioreactors Market, By Cell
Mammalian cell segment held maximum revenue shares accounting of USD 224.2 million in 2018. Mammalian cells mimic the human systems and are approximately 10 to 50-fold larger in size than microbial cells. These cells are sensitive to impurities, thus can easily be distinguished from other non-cellular components. Mammalian cells are widely used in the biopharmaceutical industry to produce biological drugs. Hence, growing demand for mammalian cells owing to higher efficiency and productivity compared to prokaryotic cells will augment segmental growth.
Yeast cell segment is witnessing lucrative growth of 15.6% during the forecast period. High growth rate is attributed to various benefits associated with yeast cells. The control of yeast flocculation is of prime importance for the brewing industry. Furthermore, various types of yeast strains when used as single culture or combined with other probiotic strains has biotherapeutic activity. The research on biomass production of probiotic yeasts in semi-industrial and industrial scale is also growing, that will drive the bioreactors market size over the forecast period.
Europe Bioreactors Market, By Molecule
Molecules produced in bioreactors include monoclonal antibodies, recombinant proteins, vaccines and stem cells. Monoclonal antibodies segment generated over USD 109.3 million in 2018. High growth is attributed to growing use of monoclonal antibodies in therapeutic applications. For instance, monoclonal antibodies are used in the treatment of breast cancers, asthma, rheumatoid arthritis, leukemia, psoriasis, transplant rejection and chronic gastrointestinal inflammatory diseases. Hence, growing applications of monoclonal antibodies in various therapeutic conditions will considerably drive Europe monoclonal antibodies market growth in the future.
Vaccines segment will grow at 17.2% from 2019 to 2025. Vaccines are one of the most effective medications for treatment of infectious diseases. Increasing infection rate and high demand for vaccines in developed countries will boost product demand. Moreover, increasing prevalence of various communicable diseases will further augment segmental growth.
Europe Bioreactors Market, By Technology
Wave-induced motion SUB segment accounted for revenue size of USD 144.6 million in 2018 and is expected to witness substantial growth across the forecast timeframe. Wave-induced motion technology is most widely used technology in modern biotechnological processes. The technology enables simple, safe and flexible production. Furthermore, increasing focus of manufacturers for development of technological advanced bioreactors will propel market growth.
Single-use bubble column technology segment is expected to witness favourable growth of 17.8% over the projected timeframe, owing to its huge demand in the biopharmaceutical industry. Bubble column bioreactors are expected to gain considerable attention in the upcoming years due to their complex hydrodynamics and influence on transport characteristics. These bioreactors are widely used as multiphase reactors in the biotechnology industry. These offer advantages such as high heat and mass transfer rates, compactness, and low maintenance costs. Hence, the above-mentioned factors will augment single-use bubble column technology segment growth.
Europe Bioreactors Market, By End-use
Biopharma manufacturers held about 31.3% of industry share in 2018. Biopharma manufacturers are estimated to experience lucrative growth across the analysis period due to increase in the number of biopharmaceutical products in pipeline such as antibodies and antibody drug conjugates. Additionally, rising number of new facilities to meet the production needs will further boost segment growth.
R&D organizations held the largest revenue of 154.2 million in 2018 and is projected to witness strong growth over the forecast years. Bioreactors are utilizing the excellent function of biocatalysts as organic catalysts; this continues to be one of the major drivers in the growing area of biotechnology. Hence, increasing promotion rate of bioreactor research programs by using biocatalysts to establish energy-saving and pollution-free process in the chemical and biopharmaceutical industry will augment R&D organizations segmental growth.
Europe Bioreactors Market, By Country
Germany bioreactors market recorded revenue size of USD 73.6 million in 2018. Factors such as presence of major players operating in the European bioreactors market along with rising venture capital investment in development of advance technology-based bioreactors in the recent years will augment bioreactors market growth in the region.
UK bioreactors market is estimated to witness substantial growth of 17.2% across the forecast period, owing to increasing technological adoption in the country and is working towards developing smart manufacturing infrastructure that will help operators to make real time use of bioreactors, thereby boosting the market growth.
Some of the major industry players involved in Europe bioreactors market include Applikon Biotechnology, Inc., Bbi-biotech, Cellexus Limited, CerCell Aps, Eppendorf AG, GE Healthcare, GEA Group Aktiengesellschaft, Merck Group, Pierre Guerin SAS, Sartorius Stedim Biotech Group, Solaris Biotech Solutions and Thermo Fisher Scientific Inc. The Europe bioreactors market is highly fragmented with many small and medium players stretched across the region. Companies mainly focus on new product launch, geographical expansion, acquisition strategy, agreements, and collaborations to stay ahead in the competition.
Europe Bioreactors Industry Background
During the initial phase, bioreactor was used as a single-use bag developed with the purpose of storage and transport. GE launched its first wave-induced bioreactor in 1996 which marked the beginning of specialized single-use bioreactors. Early 2000 witnessed limited number of products and various issues in scaling of the products but with time, technological advancements were given priority. Growing demand for innovative biotech solutions such as single-use technology, pre-built modular facilities, and the ability to revamp and upgrade existing facilities in Europe will drive the industry growth over the forecast period. Similarly, major players such as, GEA Group Aktiengesellschaft, Pierre Guerin SAS, Sartorius Stedim Biotech Group and GE healthcare are emphasizing on increasing investment in R&D for the development of new technologies that focus on improving microbial culture, mixing and temperature control.